Centogene appoints michael motz as chief commercial officer, pharmaceuticals

Cambridge, mass. and rostock, germany and berlin, may 18, 2021 (globe newswire) -- centogene n.v. (nasdaq: cntg), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced the appointment of dr. michael motz as chief commercial officer, pharmaceuticals, who will join the company on june 1, 2021.
CNTG Ratings Summary
CNTG Quant Ranking